{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of 95% CI could not be estimated due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"9.4","upperLimit":"NA","value":"12.5"},{"groupId":"OG001","lowerLimit":"5.5","upperLimit":"11.3","value":"8.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"44"}],"units":"Participants"}],"description":"DOR was defined as the time from the date of first radiographic evidence of response (CR or PR) to the earliest documented PD per RECIST v1.1 by derived investigator assessment, or death due to any cause. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR: \\>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, with minimum absolute increase of 5 mm for target disease or unequivocal progression of pre-existing lesions for non-target disease or any new lesion. Analysis was performed using Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"Phase 3: Arm B [EC + mFOLFOX6]"},{"description":"Participants received standard of care (SOC) chemotherapy per Investigator's choice: mFOLFOX6 with or without bevacizumab or FOLFOXIRI with or without bevacizumab or CAPOX with or without bevacizumab. Bevacizumab was optional and it was given per prescribing instructions of treating physician. mFOLFOX6 (28-day Cycle): fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W; FOLFOXIRI (28-day Cycle): fluorouracil 2400 or 3200 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W (per local standard of care); leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 165 mg/m\\^2 as IV infusion for 90 minutes Q2W; CAPOX (21-day Cycle): capecitabine 1000 mg/m\\^2 oral tablet twice daily on Days 1-14 and oxaliplatin 130 mg/m\\^2 IV infusion for 120 minutes Q3W.","id":"OG001","title":"Phase 3: Arm C [Standard of Care Chemotherapy, Control Arm]"}],"paramType":"MEDIAN","populationDescription":"The FAS for Phase 3, ORR subset included the first 110 participants randomized in each Arm B and Arm C. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure with a confirmed objective response by derived investigator assessment. As pre-specified in protocol of the study, this outcome measure was planned to compare DOR by derived investigator assessment between Arm B and Arm C of Phase 3. Hence, Arm A is not reported in this outcome measure.","reportingStatus":"POSTED","timeFrame":"From date of first radiographic evidence of response (CR or PR) to earliest documented PD or death due to any cause, whichever occurred first (maximum up to 24.71 months)","title":"Phase 3: DOR by Derived Investigator Assessment for Arm B Versus Arm C - FAS ORR Subset","type":"SECONDARY","unitOfMeasure":"Months"}